Skip Navigation



Cardiovascular Research Advance Access [Accepted Manuscript] published online on July 2, 2008

Cardiovascular Research, doi:10.1093/cvr/cvn183
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
80/2/181    most recent
cvn183v2
cvn183v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tamamori-Adachi, M.
Right arrow Articles by Kitajima, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tamamori-Adachi, M.
Right arrow Articles by Kitajima, S.
Related Collections
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Cardiomyocyte proliferation and protection against post-myocardial infarction heart failure by cyclin D1 and Skp2 ubiquitin ligase

Mimi Tamamori-Adachi1,*,{dagger}, Hiromitsu Takagi2,*, Kimio Hashimoto1, Kazumichi Goto2, Toshinori Hidaka2, Uichi Koshimizu2, Kazuhiko Yamada1, Ikuko Goto1, Yasuhiro Maejima3, Mitsuaki Isobe3, Keiichi I. Nakayama4, Norio Inomata2 and Shigetaka Kitajima1,{dagger}

1 Department of Biochemical Genetics, Medical Research Institute and Laboratory for Gene Structure and Regulation, School of Biomedical Science, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
2 Biomedical Research Laboratories, Asubio Pharma Co., Ltd., 1-1-1, Wakayamadai, Shimamoto-cho, Mishima-gun, Osaka, 618-8503, Japan
3 Department of Cardiovascular Medicine, Tokyo Medical and Dental University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan
4 Department of Molecular and Cellular Biology, Medical Institute of Bioregulation, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

{dagger} Correspondence should be addressed to M. T-A. (mtam.bgen{at}mri.tmd.ac.jp) or S.K. (kita.bgen{at}mri.tmd.ac.jp), Tel: +81-3-5803-5823; Fax +81-3-5803-0248.

Aims: Cyclins and other cell cycle regulators have been used in several studies to regenerate cardiomyocytes in ischemic heart failure. However proliferation of cardiomyocytes induced by nuclear-targeted cyclin D1 (D1NLS), stops after 1 or 2 rounds of cell cycles due in part to accumulation of p27Kip1, an inhibitor of cyclin- dependent kinase (CDK). Thus, expression of S-phase kinase-associated protein 2 (Skp2), a negative regulator of p27Kip1, significantly enhances the effect of D1NLS and CDK4 on cardiomyocyte proliferation in vitro. Here, we examined whether Skp2 can also improve cardiomyocyte regeneration and post-ischemic cardiac performance in vivo.

Methods and Results: Wistar rats underwent ischemia/reperfusion injury by ligation of the coronary artery followed by injection of adenovirus vectors for D1NLS and CDK4 with or without Skp2. Enhanced proliferation of cardiomyocytes in the presence of Skp2 was demonstrated by increased expression of Ki67, a marker of proliferating cells (1.95% vs 4.00%), and mitotic phosphorylated histone H3 (0.24% vs 0.58%). Compared to rats that received only D1NLS and CDK4, expression of Skp2 improved left ventricular function as measured by the maximum and minimum rates of change in left ventricular pressure, the left ventricle end-diastolic pressure, left ventricle end-diastolic volume index, and the lung/body weight ratio.

Conclusions: Expression of Skp2 enhanced the effect of D1NLS and CDK4 on the proliferation of cardiomyocytes and further contributed to improved post-ischemic cardiac function. Skp2 might be a versatile tool to improve the effect of cyclins on post-ischemic regeneration of cardiomyocytes in vivo.

KEYWORDS cardiac regeneration; cell cycle; mitotic proliferation; cyclin D1; Skp2


Time for primary review: 30

* These authors contributed equally to this work.

Abbreviations: CDK, cyclin dependent kinase: NLS, nuclear localization signal: H3P, phosphorylated histone H3: MI, myocardial infarction; FS, fractional shortening


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article

Manipulating myocyte cell cycle control for cardiac repair
Thomas A. Gorr and Alexander Deten
Cardiovasc Res 2008 80: 161-162. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Cardiovasc ResHome page
T. A. Gorr and A. Deten
Manipulating myocyte cell cycle control for cardiac repair
Cardiovasc Res, November 1, 2008; 80(2): 161 - 162.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.